Introduction
============

Cancer cells express antigens that differentiate them from their non-transformed counterparts (Van Der Bruggen et al., [@B281]). These antigens are often products of mutated cellular genes, aberrantly expressed normal genes, or genes encoding viral proteins. Categories and examples of human tumor antigens thus far identified include (a) the differentiation antigens encoded by genes that are only expressed in particular types of tissue such as those antigens expressed in melanocytes and melanoma and involved in melanin production, (b) mutational antigens that arise as a consequence of gene rearrangement and point mutations (i.e., p53), (c) cellular antigens that are over expressed in transformed cells when compared with their normal counterparts (i.e., HER-2), (d) molecules that display abnormal post-translational modifications (i.e., MUC1), (e) viral antigens derived from viral oncogenes (i.e., human papillomavirus proteins), and (f) cancer/testis (CT) antigens that are expressed in germ cells of testis and ovary but silent in normal somatic cells (i.e., MAGE and NY-ESO-1) (Cheever et al., [@B41]). It has been shown that tumors co-expressing such antigens can be recognized by effector T cells of the adaptive immune system and induce antitumor immune responses in both experimental animal and human systems (Dougan and Dranoff, [@B65]).

One of the earliest processes involved in the development of the adaptive immune response and tumor immunity is inflammation which functions to localize and eradicate tissue stressors induced by tumor growth and re-establish normal tissue homeostasis (Medzhitov, [@B176]). However, evidence obtained from various murine tumor models and clinical studies in cancer patients, have shown that chronic inflammation, mediated by ensuing adaptive immune responses, can contribute to tumorigenesis at all stages. For example, such responses may contribute to cancer initiation by generating genotoxic stress, to cancer promotion by inducing cellular proliferation, and to cancer progression by enhancing angiogenesis and tissue invasion (Grivennikov et al., [@B93]). In either instance, this forms the conceptual framework of the cancer immunoediting hypothesis, which stresses the dual host-protective and tumor-promoting actions of immunity on developing tumors (Schreiber et al., [@B250]; Vesely et al., [@B284]). In its most simplistic form, this model proposes that tumors develop through three successive and distinct phases termed "elimination," "equilibration," and "escape." The elimination phase entails the process where the innate and adoptive immune systems collaboratively detect the presence of a developing tumor and destroy it before it becomes clinically apparent. The next phase of equilibration entails the process where rare tumor cell variants survive immune-mediated elimination and enter a state of equilibrium with the adaptive immune response. In this state, the immune system maintains residual tumor cells in a functional state of dormancy, a term used to describe latent tumor cells that may reside in patients for decades before eventually resuming growth as either recurrent primary tumors or distant metastases (Aguirre-Ghiso, [@B3]). Aside from preventing tumor outgrowth, it is also believed that the immune response in this phase "fashion" the immunogenicity of the occult tumors. Lastly, in the escape phase, tumor cells that have acquired the ability to circumvent immune recognition and/or destruction emerge as progressively growing and detectable tumors. It is further postulated that the course and progression through such phases are influenced and determined, in part, by tumor cell population changes in response to the immune system, host immune system changes in response to mechanisms re-establishing cellular homeostasis, or increased cancer-mediated immunosuppression and/or immune system decline. Such local and systemic environmental stressors are thought to be the major contributors to affect not only tumor outgrowth but also immunotherapeutic interventions and their efficacy in cancer patients. Thus, the tumor-promoting inflammation and protective tumor immunity processes appear dynamically interconnected where an imbalance can further result in the shaping of tumor immunogenicity which may either initiate and/or facilitate disease progression or regression.

At the earliest stages of the antitumor immune response, professional antigen presenting cells (APCs), most notably dendritic cells (DCs), encounter and capture tumor antigens that are released from either viable or dying tumor cells. This results in the activation and up-regulation of co-stimulatory molecules that facilitate and/or promote the migration of these cells to secondary lymphoid organs such as regional draining lymph nodes (Steinman and Mellman, [@B260]; Steinman and Banchereau, [@B259]). To develop into potent CD4 effector T cells that contribute to the antitumor immune response, naïve CD4 T cells need to recognize peptide antigens presented in an immunogenic context with HLA class II molecules on activated DCs. Additional co-stimulatory signals, such as DC-derived cytokines, then promote their differentiation into effector CD4 Th cell subsets characterized by distinct cytokine secreting profiles (O'Shea and Paul, [@B217]; Zhu et al., [@B318]). The best characterized of these effector cell subsets are the Th1 and Th2 cells, which are characterized by their production of IFN-γ and interleukin-4 (IL-4), respectively. More recently, the pro-inflammatory Th9 and Th17 cell subsets have also been shown to develop and/or reside in some tumors, along with TReg cells which are responsible for immune regulation and tissue homeostasis. Following recognition of a specific tumor-associated antigen presented by an appropriately activated APC, naïve CD4 T cells undergo several rounds of division and can become polarized into such distinct effector Th cell subsets that can differentially orchestrate antitumor immune responses, in part, through their production of signature cytokines. The differentiation of polarized CD4 effector T cells is controlled by unique sets of transcription factors, the expression of which is determined by multiple signals, in particular, by soluble factors that act on responding CD4 T cells during their activation. Subsequently, such differentiation results in distinct Th cell subsets characterized, in part, by select cytokine production that can initiate, facilitate, and influence distinct mechanistic arms of the immune response to tumors as determined in several murine tumor models as well as in evidence obtained from human studies. Although the production, function, and mechanistic interplay of these signature cytokines derived from the distinct Th cell subsets will be discussed in more detail below, it is becoming increasingly clear that considerable plasticity exists among the various subsets *in vivo*, especially during responses to tumors at various stages of development, progression, and/or regression. Moreover, certain cytokines such as IL-10, can be produced by nearly all subpopulations of cells within the multiple effector cell subsets further suggesting, that CD4 T cell responses are apparently convoluted and capable of initiating and maintaining quantitatively and qualitatively variable antitumor responses involved in facilitating either direct or indirect tumor cell killing or survival.

The CD4+ T cell represents a major component of the adaptive immune response and has been shown to be an integral part in the activation and regulation processes of the host response to many pathogens. Although the role of CD4 T cells in the antitumor response remains under investigated, it is becoming clear that effective immune responses to a developing or progressing tumor requires their activation, maturation, and active participation (Pardoll and Topalian, [@B222]; Blattman and Greenberg, [@B21]; Kennedy and Celis, [@B128]; Muranski and Restifo, [@B200]). As one of their primary emerging roles as "regulators" of the immune response to cancer, CD4 T cells have been shown to orchestrate and coordinate many facets of both the innate and adaptive immune responses to ensure optimal responses by other lymphocytes. CD4 T cells are necessary elements for priming tumor-specific CD8 T cells, influencing the differentiation and expansion of tumor antigen-specific CTLs and are essential for generating and maintaining long-term CD8 memory T cell responses (Janssen et al., [@B119]; Shedlock and Shen, [@B255]; Sun and Bevan, [@B265]; Sun et al., [@B266]). Moreover, several studies have defined additional roles for CD4 T cells, some of which are independent of other lymphocytes, that influence and/or contribute to tumor immunity during carcinogenesis. Paradoxically, several experimental and clinical observations have recently shown that these same CD4 effector cell subsets and their signature cytokines can not only contribute to antitumor responses but also tumor-promoting activities. We discuss what is known about the T cell subsets that develop during different stages of tumor growth and progression, how such diverse T cell subset responses contribute to disease progression and/or regression, their development into memory cells, and their potentials in cancer treatment.

CD4 Effector T Cell Subsets
===========================

The roles of polarized CD4 T cell subsets in the antitumor immune response are greatly influenced by their signature cytokines which arm the cells with distinct immunological functions. Such cellular polarization processes are dependent, in part, on their expression of specific transcription factors that are influenced by multiple cellular and soluble biological signals within the priming milieu of the tumor environment. Moreover, substantial proportions of effector T cell subsets that are found *in vivo* are often characterized by plasticity and heterogeneity in terms of their cytokine-producing potentials. Thus effective tumor immunity is often dependent on such complex CD4 T cell responses following polarization and their interactions with other Th cell subsets within the hostile tumor environment. In any instance, the most characterized CD4 Th cell subset is the *Th1* that can potentially produce large amounts of IFN-γ upon tumor antigen encounter and expresses the transcription factor T-bet. The Th1 developmental pathway is typically driven by IL-12 activation of the signal transducer and activator of transcription 4 (STAT 4) and T-bet transcription factors during immune activation of naïve T cells (Szabo et al., [@B268], [@B269]). As the "critical regulator" of the Th1 differentiation program, T-bet is responsible for the up-regulation of the IL-12 receptor β2 (IL-12β2R) subunit and confers IL-12 responsiveness and sustained T-bet expression (Lazarevic and Glimcher, [@B148]). In addition, it induces and upregulates IFN-γ (ifnγ) production but also induces the expression of genes encoding the chemokine receptor CXCR3 and the chemokines CCL3 and CCL4 (Jenner et al., [@B120]) which are responsible for enhancing the mobilization of select type 1-related immune cell responses to sites of tumor growth. In addition, T-bet suppresses commitment to the Th2 and Th17 lineage programs (Hwang et al., [@B112]). Although IFN-γ is considered the signature cytokine for this subset in both murine and human effector T cells, other cytokines have been shown to be produced by human Th1 cells and include IL-2, TNF-α, and IL-10. Interestingly, the importance of IL-10 production by Th1 effector cell subpopulations in the antitumor response is controversial. Several recent studies have suggested that IL-10 plays a role in inhibiting tumor development, growth, and metastases (Mocellin et al., [@B190]; Emmerich et al., [@B73]; Tanikawa et al., [@B274]). Whereas others have suggested that Th1 effector cell responses are auto-regulated through a negative feedback loop via the co-induction and expression of IL-10 (Cope et al., [@B49]). Conceivably, the relative amounts and/or duration of IFN-γ and IL-10 produced by such double-positive cytokine secreting Th1 cell subsets and their ability for "cytokine switching" might define the inflammatory/immune response, tolerance induction, and/or prevention of excessive immunopathology within the tumor microenvironment.

Th2 effector cell subsets are characterized by the production of IL-4, IL-5, and IL-13 and are responsible for coordinating humoral immunity and allergic inflammatory responses. IL-4 is primarily accountable for the differentiation of Th2 cells through STAT 6 and the transcription factor GATA-3 (Kaplan et al., [@B126]; Zheng and Flavell, [@B316]; Kurata et al., [@B143]; Zhu et al., [@B317]). The Th1 and Th2 developmental pathways among naïve CD4 T cells are controlled by a delicate balance of positive feedback loops, as IFN-γ enhances further Th1 development and IL-4 supports continued Th2 differentiation. At the same time, cross regulation by IFN-γ and IL-4 suppresses Th2 and Th1 differentiation, respectively. In a murine lung metastases model, Th2 effector cells have shown some indirect antitumor activity through the eosinophil chemotactic factor, eotaxin and eosinophil tumor infiltration (Mattes et al., [@B174]). However, the role of Th2 effector cells in the antitumor immune response remains unclear with several studies suggesting that such CD4 effector cells are associated with carcinogenesis and tumor progression (Tatsumi et al., [@B276]; Ochi et al., [@B213]). Recent investigations have shown that in addition to IL-10, which is essentially produced by all Th cell subsets, a subpopulation within the Th2 subset can preferentially co-produce IL-24 (a unique member of the IL-10 cytokine family) (Schaefer et al., [@B249]; Ouyang et al., [@B219]). Although its detailed regulation in Th2 cells is currently unclear, IL-24 has been shown to lack immune repressive functions, suppress human ovarian cancer cell growth both *in vitro* and *in vivo*, and induce substantial "bystander antitumor" immunity in patients (Fisher, [@B82]; Lebedeva et al., [@B150]; Emdad et al., [@B72]; Dash et al., [@B58]). Further investigation into understanding the development and properties of IL-24-secreting Th2 cells may provide profound therapeutic benefits for cancer patients.

The expression of IL-17 characterizes a subset of CD4 helper T cells (Th17). This cell lineage represents a third effector arm of CD4-mediated immune response and complements, in part, the functions of the Th1 and Th2 cell lineages. In addition to IL-17A and IL-17F, human Th17 cells also produce other cytokines such as IL-21, IL-22, and IL-26. In addition, the chemokine receptor CCR6 \[which binds to the chemokine CC ligand 20 (CCL20) that is present in many malignant pleural effusions of lung cancer patients\] is highly expressed on Th17 cells thus further facilitating their recruitment to sites of tumor growth and inflammation (Acosta-Rodriguez et al., [@B1]; Annunziato et al., [@B7], [@B6]). Both human and murine Th17 cells express the transcription factors retinoic acid orphan receptor (ROR)γt (*Rorc*). ROR-γt is a critical regulator of Th17 cell differentiation and induces IL-17A, IL-17F, IL-26, and CCR6 expression while downregulating IFN-γ production in human naïve T cells (Manel et al., [@B169]). For induction and differentiation of murine Th17 cells, TGF-β and IL-6 are the most crucial cytokines for naïve CD4 cell differentiation (Murugaiyan and Saha, [@B202]; Gaffen, [@B87]). However, in the development of human Th17 cells, it has been shown that IL-6 and IL-1β, but not TGF-β, is essential for differentiation (Acosta-Rodriguez et al., [@B1]; Wilson et al., [@B295]). In any instance, IL-21 produced by Th17 cells further amplify Th17 generation in an autocrine manner and induce IL-23 receptor expression that enables cell responses to IL-23 stimulation. Subsequently, DC-derived IL-23 stabilizes the Th17 phenotype and helps Th17 cells to acquire effector functions. The induction of ROR-γt is dependent on STAT-3, which is preferentially activated by IL-6, IL-21, and IL-23. STAT-3 affects ROR-γt expression and binds to the IL-17 and IL-21 promoters. Thus, both STAT-3 and ROR-γt transcription factors regulate IL-17 production in a highly coordinated manner (Murugaiyan and Saha, [@B202]). In addition to characterizing Th17 cells by transcription factors and cytokine production, recent studies have shown that human Th17 cells originate from a CD4 precursor cell population that is present in both thymus and umbilical cord blood and co-expresses a member of the NK cell receptor-P1 family, CD161 (Cosmi et al., [@B51]). Although the precise function of CD161 is unknown at this time, it is considered a "hallmark" of human memory Th17 cells at sites of tissue inflammation (Cosmi et al., [@B51]; Kleinschek et al., [@B134]). Another marker that was identified to be specifically associated with human Th17 cells is the IL-4-induced gene 1 (IL-4I1) which encodes the enzyme [l]{.smallcaps}-phenylalanine oxidase. This enzyme is responsible, in part, for H~2~O~2~ production that can contribute to the inhibition of T lymphocyte proliferation (Boulland et al., [@B25]). As will be discussed below, Th17 cells are found in several human tumors. Although Th17-associated cytokines have been linked with carcinogenesis and tumor progression within the context of chronic inflammation and infection, it is becoming clear that this cell lineage can also contribute to the antitumor response in human malignancies of epithelial origin (Kryczek et al., [@B141], [@B139]; Zou and Restifo, [@B321]; Wilke et al., [@B293]).

Th22 CD4 T cells, which are thought to be a distinct Th subset that produce IL-22 independently of IL-17, were initially identified in patients with inflammatory disorders of the skin, intestine, and joints (Eyerich et al., [@B78]; Sonnenberg et al., [@B257]). More recently, such cells have also been identified and suggested to contribute to immune responses and inflammation in malignant pleural effusions and other human cancers (Zhang et al., [@B315]; Jiang et al., [@B121]; Miyagaki et al., [@B185]; Ye et al., [@B310]). Such Th22 cells express the cutaneous lymphocyte antigen (CLA), a functional E-selectin ligand that is involved in lymphocyte rolling on the endothelial cells of cutaneous postcapillary venules, along with the chemokine receptors CCR6, CCR4, and CCR10 which together facilitate the constitutive migration potentials of these cells to sites of inflammation (Duhen et al., [@B69]). Although the role, if any, of Th22 cells in the antitumor immune response is unclear, it is believed that such IL-22 producing CD4 Th cells contribute to local immune homeostasis and inflammation (Duhen et al., [@B69]).

The latest addition to the list of subsets, termed Th9, secretes IL-9 as the signature cytokine and may play a role in several inflammatory disorders. Naïve human and murine CD4 T cells both acquire a Th9 phenotype *in vitro* with the combination of IL-4 and TGF-β (Houssiau et al., [@B108]; Veldhoen et al., [@B283]; Beriou et al., [@B17]; Chang et al., [@B36]; Putheti et al., [@B228]; Yao et al., [@B308]; Jabeen and Kaplan, [@B117]; Wilhelm et al., [@B292]). The transcription factors STAT6, interferon regulatory factor 4 (IRF4), and PU.1 contribute to Th9 differentiation (Jabeen and Kaplan, [@B117]). IL-4-activated STAT6 promotes expression of IRF4 whereas PU.1 activation occurs downstream of TGF-β signaling where it directly bind to the IL-9 (*il9*) promoter (Chang et al., [@B37], [@B35], [@B36]). Interestingly, polarized Th2 cells can be deviated into Th9 cells by exposure to TGF-β, which results in down-regulation of GATA-3 and loss of IL-4 and IL-5 production. Using various gene knockout and transgenic mouse systems, Th9 cells have been shown to contribute to autoimmune and allergic inflammation processes (Noelle and Nowak, [@B209]). However, one recent study identified Th9 cells in healthy human blood and skin and also in metastatic lesions of patients with stage IV melanoma (Purwar et al., [@B227]). Moreover, using a murine tumor model, these same investigators showed that adoptive transfer of tumor-reactive Th9 cells and administration of recombinant IL-9 can effectively reduce melanoma growth. This evidence from a single study suggests that IL-9 producing Th9 cells may play a role in the generation of effective antitumor responses.

The final CD4 Th cell lineage to be described here resides in proximity to B cells within germinal centers of lymphoid tissues. These cells, referred to as follicular helper T cells (T~FH~), are responsible for providing B cell help and supporting B cell expansion and differentiation (Reinhardt et al., [@B234]; Ma et al., [@B168]). They are defined by expression of the transcription factor Bcl6 and the cytokines IL-21 (Liu et al., [@B158]). Moreover, they express the chemokine receptor CXCR5 which facilitates migration to the B cell follicles after activation (Chtanova et al., [@B46]; Haynes et al., [@B101]). Studies have also shown that they possess key surface receptor molecules (PD-1, CD40 ligand, OX-40, CD84, and ICOS) that play critical roles in promoting B cell activation, differentiation, and survival (Ma et al., [@B168]). However, the role of T~FH~ cells in tumor immunity remains relatively undefined.

Accumulating evidence suggests that select CD4 effector T cell subsets may have a more "direct" role in inhibiting tumor growth and progression that are independent of their more "indirect" helper activities. As such, CD4 effector T cells have, in general, been shown to protect against both tumors and virally infected target cells through two distinct primary effector mechanisms. They include the production of cytokines, most notably IFN-γ and TNF (Hung et al., [@B111]; Pardoll and Topalian, [@B222]) and through direct cytolytic activity (Trapani and Smyth, [@B280]) that is mediated by degranulation of cytotoxic granules containing toxic effector molecules (i.e., perforin and granzyme) or ligation of the Fas (also known as CD95)/Fas Ligand (FasL; also known as CD95L) apoptotic killing pathway (Green and Ferguson, [@B92]). *Cytolytic CD4* T cells possessing such cytotoxic activity have been described in peripheral blood of both healthy and virally infected individuals (Feighery and Stastny, [@B81]; Appay et al., [@B10]; van Leeuwen et al., [@B282]; Casazza et al., [@B34]; Stuller and Flano, [@B264]; Nemes et al., [@B205]; Stuller et al., [@B263]). Phenotypic analysis has shown that they are CD45RO^+^, CCR7^−^, CD27^−^, and CD28^−^ and shown to possess high levels of the cytolytic effector molecules granzyme A, granzyme B and perforin (Appay et al., [@B10]; Casazza et al., [@B34]) suggesting that these cells are antigen-experienced and terminally differentiated CD4 effector cells. Moreover, as with CD8 effector T cells (Pearce et al., [@B223]; Intlekofer et al., [@B115]), there is evidence that expression of the eomesodermin (*Eomes*) transcription factor may be crucial in driving the development of cytotoxic CD4 T cells *in vivo* (Qui et al., [@B231]; Hirschhorn-Cymerman et al., [@B104]). Although T cell expression of eomesodermin has been linked to terminal differentiation and memory cell phenotype with the concomitant secretion of Th1 cytokines (Hirschhorn-Cymerman et al., [@B104]), others have suggested that cytotoxic activity of CD4 effector T cells does not depend on Th1 cell polarization (Brown et al., [@B27]). Thus suggesting that such cells constitute a unique and separate cell lineage from those already described. In either instance, more recent studies using a murine transgenic tumor model of advanced melanoma, showed that transfer of naïve tumor-reactive CD4 T cells into lymphopenic recipients can induce a substantial expansion and differentiation of Th1 cells with cytotoxic activity (Quezada et al., [@B230]; Xie et al., [@B304]). Moreover, induction of such cells correlated with class II-restricted tumor rejection that was dependent on the presence of IFN-γ which was believed to mediate the up-regulation of class II on tumor target cells. In more recent studies using both human and murine cells, generation of tumor-reactive cytotoxic CD4 Th1 cells were further shown to be induced, in part, by both the engagement of a specific co-stimulatory pathway of the tumor necrosis factor receptor (TNFR) family member, OX-40 (also known as CD134) and an intracellular mechanism relying on eomesodermin expression (Qui et al., [@B231]; Hirschhorn-Cymerman et al., [@B104]). Further identification and characterization of the mechanisms involved in the induction of tumor-reactive CD4 T cells with cytotoxic activities in cancer patients may offer significant advantages for future treatment strategies of human malignancies.

Lastly, the subpopulations of CD4^+^ TReg cells can be classified into two main subsets according to their origin and suppressive activity. Natural CD4^+^ TReg effector cells (nTRegs), constitutively expressing FoxP3 and the activation marker CD25, originate in the thymus by high affinity interaction of the T cell receptor (TCR) with Ag expressed on the thymic stroma (Sakaguchi, [@B241]; Shevach, [@B256]; Buckner, [@B28]; Nishikawa and Sakaguchi, [@B207]; Sakaguchi et al., [@B242]; Miyara and Sakaguchi, [@B187]). Such cells suppress the proliferation of effector T cells in a contact-dependent, cytokine-independent manner. In contrast, other types of TReg cells can be induced from naive CD4 cells in the periphery, such as IL-10-producing TR1 cells and TGF-β-producing Th3 cells (Groux et al., [@B95]; O'Garra et al., [@B215]; Grazia-Roncarolo et al., [@B91]; Nishikawa and Sakaguchi, [@B207]). Such "induced" CD4^+^CD25^−^ TReg subpopulations (iTReg) exert suppression mostly through soluble factors and their suppressive function is not strictly associated with a high level of FoxP3 expression. Moreover, human TReg cell subpopulations have also been further divided into two subsets based on their expression of the "resting" CD45RA (a marker of naïve or antigen-inexperienced cells) or "activated" CD45RO (a marker for memory or antigen-experienced T cells) cell surface markers (Vukmanovic-Stejic et al., [@B288]; Miyara et al., [@B188]; Miyara and Sakaguchi, [@B187]; Duhen et al., [@B68]) further suggesting different levels of activation and/or differentiation among these CD4 subsets. More recently, another inducible subpopulation of the CD4^+^ TReg cell subset have been reported in both human and murine systems that involve production of IL-35 and are thus referred to as iTreg35 cells (Collison et al., [@B48]; Chaturvedi et al., [@B39]). Notably, these cells are phenotypically and functionally distinct from other subpopulations of TReg cells described thus far in that they do not express FoxP3 and they mediate immunosuppression via IL-35 and seemingly independent of IL-10, TGF-β, the immunomodulatory receptor CTLA-4, or any other currently known TReg cell-associated suppressive molecule. Although it seems that human nTReg cells do not express IL-35 (Bardel et al., [@B13]), naïve human CD4 T cells can be induced to develop into iTReg35 cells in the presence of IL-35 or activated DCs (Collison et al., [@B48]; Seyerl et al., [@B252]). Alternatively, it has been suggested that human TReg subpopulations can be further classified by their expression of select chemokine receptors that correspond to Th cell lineage-specific immune responses (Duhen et al., [@B68]). For example, TReg subpopulations co-expressing CCR6 (Th17-associated responses), CXCR3 (Th1-associated responses), CCR4 (Th2-associated responses), and CCR10 (Th22-associated responses) enable human TReg cell subpopulations with unique specificities and immunomodulatory functions to target defined immune environments during different types of inflammatory responses so as to exert an "appropriate" regulatory process. Thus, suggesting that Th and TReg cells undergo functional specialization in parallel, resulting in the development of TReg cell subpopulations capable of co-localizing and effectively regulating different types of Th cell responses *in vivo* (Hall et al., [@B98]; Duhen et al., [@B68]). In any instance, the precise mechanisms by which these various subpopulations of TReg cells function to maintain the balance between protective tumor immunity and establishing or rebalancing immune cell homeostasis remains poorly understood. However, several mechanisms responsible for preventing inflammatory disease by restraining aberrant responses to self or innocuous antigens have been identified (Vignali et al., [@B287]; Shevach, [@B256]; Qureshi et al., [@B232]; Yamaguchi et al., [@B306]; Vignali, [@B286]; Wing and Sakaguchi, [@B296]). These include both cell contact and soluble factor-dependent mechanisms, such as production of IL-10; the production and surface expression of TGF-β; the production of IL-35; the release of cytolytic molecules such as granzyme and perforin; the consumption of IL-2 through the high density expression of cell surface CD25 (the alpha chain of the IL-2 receptor) which weans effector T cells from IL-2; the degradation of ATP through ectonucleotidases; and expression of the inhibitory receptors CTLA-4, which outcompetes receptor CD28 on effector T cells for access to the co-stimulatory molecules CD80 and CD86 on APCs.

CD4 Memory T Cell Development and Their Role in the Antitumor Response
======================================================================

During the antitumor response a small population of tumor-specific CD4 effector T cells may develop into memory T cells that retain their previous effector functions and rapidly produce effector cytokines (McKinstry et al., [@B175]; Taylor and Jenkins, [@B277]; Strutt et al., [@B262]). Their ability to remember previously encountered antigens leads to faster responses to tumor antigen re-exposure and thus may play a role in preventing disease relapse in cancer patients. Alternatively, as discussed earlier, it can shape tumor cell immunogenicity and modulate immune response dynamics to influence disease progression (Schreiber et al., [@B250]; Vesely et al., [@B284]). In humans, different isoforms of the CD45 molecule are often used to differentiate naïve and memory cells with the former expressing CD45RA and the latter expressing CD45RO (Ahmed and Gray, [@B4]). Increased expression of other surface molecules such as the CD95 death receptor has also been shown to differentiate memory cells from naïve CD4 T cells. Moreover, memory T cells have been divided into two general subgroups based on their patterns of migration (Sallusto et al., [@B244]). Central memory T cells (T~CM~) express the CC-chemokine receptor CCR7 and L-selectin CD62L following activation. Expression of these receptors enable the T~CM~ subgroup to recirculate through secondary lymphoid organs such as lymph nodes. Such circulation is beneficial since DCs from diverse tissue sites continuously bring antigen to the draining lymph nodes, thereby increasing the effective area of memory cell immunosurveillance for progressing tumor growth due to metastases and/or occult cell outgrowth. Alternatively, effector memory T cells (T~EM~) lack expression of CCR7 or CD62L and thus have a propensity to migrate to peripheral tissues in response to localized inflammatory stimuli and bolster the process of immune surveillance at such sites. Moreover, expression of other surface chemokine receptors such as CCR5 have been associated with polarized Th1 memory T cell subsets (Loetscher et al., [@B163]; Sallusto et al., [@B245]; Kim et al., [@B131]; Luther and Cyster, [@B167]; Charo and Ransohoff, [@B38]). In either instance, retention and tissue tropism of memory CD4 T cell subsets and their diverse functional capacities are dependent, in part, on specific interactions between adhesion molecules and effector cell chemokine receptors that induce T cell subset localization and influence tumor environments. This has been shown in studies with cancer patients where increased intratumoral memory T cell levels were associated with longer disease free and overall survival rates (Pagès et al., [@B220]; Bindea et al., [@B20]). In another study involving colon cancer patients, histopathological analysis showed the presence of "patches" of T~EM~ cells located within either the center or invasive margins of the tumor that further correlated with good clinical outcome (Galon et al., [@B88]). These investigators suggested that memory cell localization at select regions within the tumor mass may be associated with not only enhanced antitumor immune responses but also effective control of metastatic escape. However, as briefly mentioned earlier, such observations and effective antitumor responses may not only depend on memory cell phenotype and localization, but also their functional memory precursor phenotype and ability for "cellular plasticity" within the hostile tumor environment.

In addition to surface markers, differential expression levels of select transcription factors have been associated with promoting effector and memory T cell development. In studies using various genetically modified mouse strains, investigators have shown that under conditions of inflammation, elevated levels of the transcription factor T-bet (*Tbx21*) among responding CD8 T cells promoted the generation of terminally differentiated short-lived effector cells whereas lower levels facilitated long-lived, self renewing memory T cell development (Joshi et al., [@B123]; Lazarevic and Glimcher, [@B148]). In more recent studies, it was shown that IL-12 augmented activity of the kinase mammalian target of ramamycin (mTOR) (Rao et al., [@B233]; Cox et al., [@B53]) which is essential for sustained T-bet expression and the generation of effector CD8 T cells. Subsequently, inhibition of mTOR activity blocked T-bet expression and promoted elevated and sustained levels of the closely related T-bet transcription factor eomesodermin (*Eomes*) that is associated with the development of memory T cells (Pearce et al., [@B223]; Intlekofer et al., [@B115], [@B114]; Joshi et al., [@B123]; Rao et al., [@B233]). Moreover, over-expression of eomesodermin or T-bet has been shown to be sufficient to induce expression of IFN-γ, perforin, and granzyme B in CD8 T cells (Pearce et al., [@B223]; Cruz-Guilloty et al., [@B55]). Thus suggesting that (i) the transcription factors T-bet and eomesodermin have cooperative and partially redundant functions in CD8 T cell differentiation and fate (Rao et al., [@B233]) and (ii) the balance between the two transcription factors, as "instructed" by mTOR kinase activity, can determine the CD8 effector cell fate verses memory cell fate (Araki et al., [@B11]; Rao et al., [@B233]). Although the transition of CD4 effector to memory T cell phenotype is less defined, evidence using a murine viral infection model has shown a similar correlation with decreased T-bet (Tbx21) expression levels and potential Th1 memory cell development (Marshall et al., [@B170]). Furthermore, in a mouse model of allergic airway inflammation, IL-5 production among a Th2 memory cell subpopulation was shown to be uniquely regulated by the expression of eomesodermin (*Eomes*) suggesting a role for this transcription factor in the regulation of polarized CD4 T cell functions (Endo et al., [@B74]). Whereas, in a study using peripheral blood from healthy human donors, expression of T-bet was shown to be up-regulated among specific Th1 memory cell subpopulations following TCR stimulation whereas elevated expression levels of eomesodermin (*Eomes*) were associated with a higher level of IFN-γ production during the recall response in a corresponding cell subpopulation (Narayanan et al., [@B204]). Lastly, similar results were observed in the murine system suggesting a role for Eomesodermin (*Eomes*) in the development of Th1 cell differentiation and memory phenotype under various stimulating conditions *ex vivo* (Suto et al., [@B267]; Yang et al., [@B307]; Hirschhorn-Cymerman et al., [@B104]). Collectively, it is unclear which responding CD4 effector T cells make the transition to a memory phenotype, but these recent studies suggest that differential expression levels and balance between transcription factors promote and/or facilitate the T cells potential to do so. In either instance, this "phenotypic progression" from effector to memory T cell provides a qualitative advantage in the antigen-specific antitumor response by enhancing immune response time, the need for less co-simulation and more vigorous proliferation especially at lower levels of tumor antigen exposure when compared to that of antigen-inexperienced T cells.

Helper Functions and the Potentially "Good" and "Bad" Sides of CD4 Effector T Cell Subsets in the Antitumor Immune Response
===========================================================================================================================

Although the best studied pathways of CD4 T cell-mediated help are those that promote antibody production by B cells, such cells also enhance tumor-specific CD8 T cell responses during disease progression and contribute to the maintenance of a functional memory CD8 T cell pool (Pardoll and Topalian, [@B222]). Various CD4 T cell subsets can also alter the function of APCs (especially DCs) and innate immune cells (Hung et al., [@B111]). In addition to enhancing and/or regulating T cell-mediated responses, that include both promoting long-term immunity and establishing or rebalancing immune cell homeostasis, CD4 T cells can also have a direct role in tumor elimination (Pardoll and Topalian, [@B222]; Quezada et al., [@B230]; Xie et al., [@B304]). Paradoxically, several experimental and clinical observations have recently shown that such CD4 effector cell subsets and their signature cytokines can not only contribute to effective antitumor responses but also facilitate tumor-promoting activities. In this section of the review, we will discuss these points and focus on the three most studied and potentially most promising CD4 effector T cell subsets involved in antitumor immunity and therapy, namely the Th1, Th17, and TReg cell subsets.

The Th1 and IFN-γ Paradox
-------------------------

Th1 cells are potent inducers of cell-mediated immunity and inflammation. Through studies using various murine tumor models, Th1-mediated immune responses have been shown to participate and facilitate in the elimination of established tumors and reduce tumor development and susceptibility to carcinogenesis. Moreover, it has been observed in studies of patients with various cancer types that favorable clinical outcomes, as assessed by disease free and overall survival, can be attributed to an enhanced and coordinated Th1 effector cell infiltration within the tumors of these patients (Fridman et al., [@B84]). IFN-γ is produced predominantly by the Th1 CD4 effector T cell subset. Tumor antigen-specific Th1 cells control tumors, in part, through the secretion of IFN-γ that can have both direct and indirect effects on immune activation and modulation (Mumberg et al., [@B195]; Zaidi and Merlino, [@B312]). IFN-γ derived from Th1 cells can induce a cascade of events involving the priming and maturation of cytolytic CD8 T cells through activation of DCs at the sites of tumor growth and further induce tumor elimination through activation of NK cells and type 1 macrophages (Corthay et al., [@B50]; Quezada et al., [@B230]; Palucka and Banchereau, [@B221]). Moreover, IFN-γ can induce development of the Th1 cell lineage, rather than the potentially tumor-promoting Th2 lineage, and further promote expression of the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10, and CXCL11 that can specifically attract and enhance Th1 cell localization to sites of tumor growth and inflammation (Rotondi et al., [@B237]). Other studies have suggested that IFN-γ actually inhibits the generation and/or activation of naturally occurring TReg cell subsets (Nishikawa et al., [@B206]; Caretto et al., [@B32]). Similarly, another group showed IFN-γ signaling caused cell cycle arrest in TReg cells suggesting that this IFN-γ-dependent mechanism could counteract the ability of TReg cells to protect tumors in cancer patients (Cao et al., [@B30]). Aside from its immune stimulatory roles and affects on various T cell subpopulation dynamics, IFN-γ can up-regulate HLA class I and class II molecules on tumor cell populations that aid in facilitating cytolytic T cell recognition and elimination of tumors. Studies in both human and murine systems have shown IFN-γ to inhibit cancer cell proliferation (Bromberg et al., [@B26]; Chin et al., [@B45]; Hobeika et al., [@B106]; Platanias et al., [@B225]; Zaidi and Merlino, [@B312]), promote tumor cell apoptosis through effects on the expression of caspases, FAS (also known as CD95), and TRAIL (Takeda et al., [@B272]; Chin et al., [@B44]; Xu et al., [@B305]; Meng and El-Deiry, [@B179]), and inhibit angiogenesis within the tumor environment (Luster and Leder, [@B165]; Coughlin et al., [@B52]; Ruegg et al., [@B239]. Beatty and Paterson, [@B15]). With respect to angiogenesis, IFN-γ is a potent inducer of several angiostatic chemokines, such as CXCL9 and CXCL10, from a variety of cells, including monocytes, macrophages, fibroblasts, endothelial cells, and tumor cells (Luster and Ravetch, [@B166]; Farber, [@B80]; Arenberg et al., [@B12]; Cole et al., [@B47]). This may contribute to a shift the local biologic balance between angiogenic and angiostatic chemokines that results in anti-angiogenesis and tumor-associated vascular inhibition. Of course, the different IFN-γ-inducible processes and effects, that are responsible for directly limiting tumor growth and progression, are not only dependent on tumor type, but also cytokine concentration and expression of the extracellular domains of the IFN-γ receptor subunits and their intracellular signaling transmission pathways among the various cells within a dynamic tumor environment (Ealick et al., [@B71]; Boehm et al., [@B22]).

Alternatively, a dual role for IFN-γ in the context of malignancy has been reported and associated with contributing to enhanced tumor growth and metastases (Dunn et al., [@B70]; Schreiber et al., [@B250]). Several reports have suggested that IFN-γ, possibly derived from Th1 cells, can up-regulate the surface expression of the immunoinhibitory molecule B7-H1 on tumor-associated APCs (Dong et al., [@B64]; Liu et al., [@B155]; Zou and Chen, [@B320]; Wu et al., [@B301]; Kondo et al., [@B136]). Under such conditions, cross-talk between these APCs and T cell expressing the corresponding ligand, PD-1, could result in a coordinated suppressive and tolerogenic environment. In addition, it has been shown that T cell-derived IFN-γ can interact with tumor cells and tumor-associated APC to induce the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme that degrades the essential amino acid tryptophan that leads to the suppression of T cell immunity (Carlin et al., [@B33]; Munn et al., [@B197]; Fallarino et al., [@B79]; Zou, [@B319]; Sharma et al., [@B254]; Mellor and Munn, [@B177]; Muller et al., [@B194]). It has been shown that IFN-γ can enhance the presence of myeloid-derived suppressor cells (MDSC), in an IFN-γ-dependent manner, within the tumor microenvironment resulting in the suppression of T cell responses (Ostrand-Rosenberg and Sinha, [@B218]; Gabrilovich et al., [@B86]). Lastly, it has been reported that IFN-γ can facilitate and/or mediate either contraction of the CD4 T cell population via induction of apoptosis (Berner et al., [@B19]) or up-regulate and induce the development of TReg cells (Agnello et al., [@B2]; Liu et al., [@B159]; Campbell and Koch, [@B29]). Such IFN-γ-mediated activity derived from Th1 cells infiltrating sites of tumor growth can conceivably undermine the antitumor immune response by negatively affecting T cell population dynamics *in vivo*. For example, Th1 cells may possess homeostatic functions under select conditions within the tumor that can influence the generation, survival and balance of CD4 and CD8 effector and memory T cell subpopulation pools necessary for effective antitumor responses. Consequently, such immune-mediated effects on the local tumor environment could be responsible for the promotion of tumor cell dormancy and contribute to the maintenance, potential progression and/or re-emergence of occult tumor cells or cancer-related stem cells (Mellor and Munn, [@B177]; Schreiber et al., [@B250]).

Finally, with regards to clinical application, recombinant IFN-γ was initially used to treat chronic myelogenous leukemia, alone and in combination with IFN-α, but failed to show any significant positive outcome (Kurzrock et al., [@B145]; Kloke et al., [@B135]). Since then, recombinant IFN-γ has been used in the clinical management of a variety of malignancies including bladder carcinoma, colorectal cancer, ovarian cancer, and adult T cell leukemia; however, the results have been mixed (Miller et al., [@B184]). In melanoma patients, early small scale clinical trials were largely inconclusive (Creagan et al., [@B54]; Ernstoff et al., [@B77]; Kowalzick et al., [@B138]; Kopp et al., [@B137]). In another trial for adjuvant application in patients with melanoma, studies were prematurely terminated due to the observations that IFN-γ-treated patients fared worse than the untreated population (Meyskens et al., [@B182], [@B183]). Although the clinical application and therapeutic effects of directly administered recombinant IFN-γ in cancer patients appears marginal, there is limited experience in investigations focused on therapies utilizing direct transfer of tumor-reactive CD4 T cells secreting IFN-γ. Several earlier clinical studies utilizing various T cell transfer therapies have suggested that the incorporation of CD4 T cells would heighten therapeutic efficacy and improve clinical outcome (Walter et al., [@B289]; Dudley et al., [@B66]; Ho et al., [@B105]; Levine et al., [@B153]; Kershaw et al., [@B129]; Bollard et al., [@B23]). One of the initial clinical studies showing autologous IFN-γ producing CD4 T cell transfer as an effective therapeutic agent in cancer patients was performed by Hunder et al. Using an autologous CD4 T cell clone with specificity to the melanoma-associated antigen NY-ESO-1, these investigators showed that transferred tumor-reactive IFN-γ-producing CD4 T cells mediated a durable clinical remission and promoted endogenous responses against melanoma antigens other than NY-ESO-1 in a melanoma patient (Hunder et al., [@B110]). Furthermore, the patient experienced a complete response with persistence of the transferred cells and a concomitant induction of melanoma antigen-reactive CD8 T cells. In our adoptive T cell therapy studies with late stage ovarian cancer patients, using peripheral blood-derived MUC1 peptide-stimulated Th1-like effector T cells, we reported that autologous T cell re-stimulation and subsequent intra-peritoneal re-infusion modulated endogenous T cell-mediated immune responses and systemic T cell subpopulation dynamics that were associated with enhanced patient survival (Dobrzanski et al., [@B63]). In spite of the limited numbers of such studies investigating CD4 T cell based immunotherapy in cancer patients, it is becoming apparent that Th1 cells possess the capacity to modulate the immune response and potentially enhance tumor immunity in the clinical setting.

The immunomodulation paradox of IL-10 derived from CD4 effector T cells
-----------------------------------------------------------------------

Several studies support the view that IL-10 may diminish the immune response against cancer by directly inhibiting cell activation of select human T cell subpopulations (de Waal Malefyt et al., [@B59]; Taga et al., [@B270]; Joss et al., [@B124]). IL-10 can also act as a negative mediator in the cross-talk between innate and adaptive antitumor immunity. For example, it has been reported that the IL-10 immunosuppressive activity on T cells is mainly indirect and is functionally linked to other immune cells such as TReg cells, MDSC, and APCs. In the case of APCs, IL-10 restrains antigen presentation via its inhibition of MHC and co-stimulatory B7 family member molecules (Vicari and Trinchieri, [@B285]; O'Garra and Murphy, [@B214]), stimulates up-regulation of inhibitory B7 family members (Curiel et al., [@B57]; Kryczek et al., [@B142]; Zou and Chen, [@B320]), down-regulates IL-12 production, and inhibits DC maturation and differentiation (Moore et al., [@B192]). *In vitro* studies have shown that T cells can be anergized toward melanoma-associated antigens when stimulated with IL-10 conditioned DCs (Steinbrink et al., [@B258]), and DCs which infiltrate progressing melanoma metastases in humans, have been characterized to express low levels of CD86 and IL-12 but possess an enhanced capacity to produce IL-10 (Enk et al., [@B75]). Moreover, IL-10 producing monocytes and select populations of the myeloid lineage, which inhibit T cell proliferation, have been isolated from the ascites of patients with ovarian carcinomas (Loercher et al., [@B162]). These cells and their subpopulations, such as MDSCs, can promote the local clonal expansion and/or induce conversion of naïve CD4 T cells into TReg cell populations (Gabrilovich et al., [@B86]). Moreover, it has been reported that the CD4^+^ Tr1 regulatory cells produce antigen-driven IL-10 that is responsible for peripheral immune tolerance through the impaired activation and regulation of CTL, Th1, and other effector Th cell subsets that further facilitate elevated tumor growth through immune escape mechanisms (Seo et al., [@B251]). It is now clear that IL-10 can not only mediates inducible TReg cell immunosuppressive activity but also plays a direct role in their genesis (Roncarolo et al., [@B235]). *In vitro* studies have shown that IL-10 treatment can convert different types of tumor cells, such as melanoma and lymphoma, to a CTL-resistant phenotype by decreasing the expression of HLA class I molecules on their surface (Petersson et al., [@B224]; Kurte et al., [@B144]). Similarly, IL-10 production by human basal and squamous cell carcinoma prevents *in vitro* lysis of autologous malignant cells by cytolytic T lymphocytes (Kim et al., [@B132]). Lastly, recent studies have shown that endogenous IL-10 can potentially limit the pro-tumor and/or antitumor effects of Th17-mediated inflammation either indirectly by promoting the regulatory functions of both FoxP3^+^ and FoxP3^−^ cells or directly by interacting with IL-10 receptors on Th17 cells in an IL-10 signaling-dependent manner (Chaudhry et al., [@B40]; Huber et al., [@B109]). Collectively these studies in both the animal and human systems suggests that IL-10 is involved in both direct and indirect tumor immunosuppressive networks that can promote and facilitate tumor immune tolerance resulting in malignant progression.

Although IL-10 is generally regarded as an anti-inflammatory and immunosuppressive cytokine that favors tumor escape from immune surveillance, evidence is accumulating that IL-10 also possesses immunomodulatory properties that support antitumor immunity. For example, transfection of tumor cells with IL-10 or systemic administration of exogenous IL-10 significantly suppressed tumor growth and led to tumor rejection in several different murine tumor models *in vivo* (Giovarelli et al., [@B90]; Berman et al., [@B18]; Fujii et al., [@B85]; Mumm et al., [@B196]). Moreover, such antitumor effects of IL-10 were dependent on CD8 T cells. *In vitro* studies have further shown that IL-10 can induce proliferation and cytotoxic activity of human CD8 T cells and function as a chemoattractant for CD8 T cells (Chen and Zlotnik, [@B43]; Jinquan et al., [@B122]; Groux et al., [@B94]; Santin et al., [@B247]). In more recent studies using IL-10 and IL-10 receptor knockout and transgenic mouse strains, investigators reported that IL-10 directly mediated intratumoral activation and expansion of resident tumor-reactive CD8 T cells that independently rejected established tumor growth and progression (Emmerich et al., [@B73]). Alternatively, another group using IL-10 knockout mice showed that IL-10 indirectly hindered tumor development, growth, and progression by impeding the development of both MDSCs and CD4^+^ TReg cells which presumably contributed to immune suppression, carcinogenesis, and tumor pathology (Tanikawa et al., [@B274]). Lastly, recombinant IL-10 has been associated with stimulating pro-inflammatory responses, such as IFN-γ production, when administered to humans (Lauw et al., [@B146]; Tao et al., [@B275]; Tilg et al., [@B278]). Since it is clear that nearly all CD4 effector T cell subsets can potentially produce IL-10, it is conceivable that endogenous IL-10 (such as IL-10 derived from CD4 helper/effector T cells infiltrating sites of tumor growth) may exhibits both antitumor and pro-tumor activities (Mocellin et al., [@B191]). Under both scenarios, IL-10 may influence tumor cells through the development, recruitment, and/or activation of various immune response cells, including tumor-reactive CD8 and other CD4 effector T cell subsets. Alternatively, a body of both clinical and pre-clinical data is emerging showing that IL-10 can influence tumor growth and progression by non-immune-related phenomena such as the inhibition of angiogenesis and induction of tumor cell apoptosis (Mocellin et al., [@B190]). In either instance, the role of endogenous IL-10 as a mediator of either tumor escape or successful immune surveillance may depend upon the conditions of initial carcinogenesis and tumor type, level of tumor progression, and the presence of responding immune cell populations at the sites of tumor growth.

Many CD4 Th cell subsets can potentially produce IL-10, as well as their hallmark cytokines, following engagement of their TCR with antigen (Sariava and O'Gara, [@B248]). The presence of reactive tumor infiltrating CD4 helper T cells have been associated with good clinical outcomes in patients with select cancer types (Pagès et al., [@B220]). Interestingly, this broaches the possibility that IL-10-derived from such Th cells may act, in part, as an immunological adjuvant in the antitumor response to cancer. A subset of Th1 cells has been identified in both murine and human systems and found to either stably or transiently produce both IL-10 and IFN-γ during periods of chronic inflammation and disease (Jankovic et al., [@B118]; Cope et al., [@B49]). Several signals have been found to stimulate the generation of such dual cytokine-expressing effector cell subpopulations, including high levels of antigen, soluble factors such as IL-12 and IL-27, and co-stimulatory signals such as ICOS (Jankovic et al., [@B118]). More recently, it has been suggested that such cytokine switching and/or co-expression in both human and mouse cells of the Th1 lineage may be linked to the role of the complement regulator and T cell co-stimulatory molecule, CD46 with the addition of either TCR engagement or high amounts of IL-12 (Meyaard et al., [@B181]; Cardone et al., [@B31]). In either instance, it has been suggested that Th1 effector cell responses are auto-regulated through not only extrinsic but also intrinsic negative feedback loops via the co-induction of IL-10 and IFN-γ. Thus, it is conceivable that the relative amounts and/or duration of IFN-γ and IL-10 produced by such double-positive cytokine secreting effector cell subsets might define the antitumor and/or inflammatory immune response within the tumor microenvironment that results in either tumor eradication or tolerance induction and disease progression. In our recent studies investigating the therapeutic role of adoptively transferred Th1-like effector cells in patients with ovarian cancer, we reported that autologous IFN-γ-secreting CD4 effector cells used in the treatment of long-term surviving patients co-produced higher levels of CD4 effector cell-derived IL-10 when compared to that of short-term survivors. We suggest that such heightened or variable levels of effector cell-derived IL-10, either in combination with IFN-γ or alone, may contribute, in part, to enhancing patient antitumor responses by modulating select effector T cell subsets, such as CD4^+^ TReg cells and their subpopulations. Conceivably, such modulation in effector cell population dynamics could affect the balance between effective and ineffective antitumor responses and patient survival. Although the molecular mechanisms and roles underlying the effects of IL-10 have not been well characterized, the biological activities of IL-10 in tumor immunity and pathology appear highly context-dependent.

The Th17 and IL-17 paradox
--------------------------

IL-17 secreting Th cells (Th17) have been implicated in promoting inflammation responsible for immunopathology in both cancer and several autoimmune disorders. Studies in various murine tumor models have suggested that Th17 cells may be associated with tumor initiation and growth in the context of chronic inflammation (Kawakami et al., [@B127]; Wang et al., [@B290]; Wu et al., [@B302]). In patients with hormone-resistant prostate cancer, an inverse correlation has been reported between pretreatment circulating levels of Th17 cell numbers and time to disease progression suggesting that Th17 cells may accelerate tumor development in such patients (Derhovanessian et al., [@B61]). Alternatively, others have suggested that Th17 cells may contribute to protective antitumor responses in select human malignancies whereas Th17-associated cytokines may be the contributing factors related to tumor initiation and growth. In studies utilizing various genetically modified murine tumor models, investigators have shown that endogenous IL-17 (such as IL-17 derived from Th17 cells infiltrating sites of tumor growth) could promote tumor growth by inducing tumor vascularization, suggesting that the cellular targets of IL-17 in the tumor microenvironment can be vascular endothelial cells, stromal cells, and cells of the tumor itself (Numasaki et al., [@B210]; Wilke et al., [@B293]). Later studies showed that IL-17 induced a wide range of angiogenic mediators (Numasaki et al., [@B211]; Takahashi et al., [@B271]; Honorati et al., [@B107]), including vascular endothelial growth factor (VGEF), that markedly promotes inflammation and tumor angiogenesis. Alternatively, IL-17 has been shown to induce IL-6 production from tumor cells and tumor-associated stromal cells, which in turn activate STAT-3, an oncogenic transcription factor that upregulates pro-survival and pro-angiogenic gene levels in transformed cells (Wang et al., [@B290]). Furthermore, IL-17 has been shown to selectively enhance the production of angiogenic chemokines such as CXCL1, CXCL5, CXCL6, and CXCL8 in tumor cells and epithelial cells (Numasaki et al., [@B212]; Lee et al., [@B151]). Thus, the biological activities and tumor-promoting effects of endogenous IL-17-mediated inflammatory responses appear to be dependent on differences in local cytokine concentrations, bioavailability, and presence of select responding target tissues. Moreover, IL-17 appears highly context-dependent with respect to tumor type, stages of development, and host immune status as cytokine-mediated effects have been shown to be heightened in immunocompromised animals (Murugaiyan and Saha, [@B202]).

Alternatively, pre-clinical murine tumor studies have correlated the presence of intratumoral Th17 cells with reduced tumor growth and effective antitumor immunity (Muranski et al., [@B198]; Martin-Orozco et al., [@B173]). Polarized Th17 cells have been observed in distinct human cancer types, including colon, melanoma, pancreatic, hepatocellular, and ovarian (Kryczek et al., [@B139]). In clinical studies, patients with advanced ovarian cancer were observed to possess elevated levels of both intratumoral Th17 cell numbers and IL-17 concentrations within patient ascites that correlated with improved survival (Kryczek et al., [@B139]; Wilke et al., [@B293]). Similar results have been observed in patients with other malignancies suggesting a beneficial role for Th17 cells in cancer (Sfanos et al., [@B253]; Ye et al., [@B311]; Chen et al., [@B42]). Moreover, Th17 cells have been observed to be negatively correlated with TReg cells and positively correlated with effector immune cells including IFN-γ-secreting Th1 cells, cytotoxic CD8 T cells, and NK cells within the tumor microenvironment (Kryczek et al., [@B139]; Zou and Restifo, [@B321]; Wilke et al., [@B293]). However, their roles and mechanisms of action in the antitumor response are not well understood. It has been suggested that possible protective mechanism(s) mediated by Th17 cells include their capacity to secrete multiple and functionally distinct cytokines such as IL-17A, IL-17F, IL-22, and IL-21. For example, IL-21 production has been shown to sustain CD8 T cell responses (Moroz et al., [@B193]; Zeng et al., [@B314]; Frederiksen et al., [@B83]). Moreover, Th17 cells have been shown to produce the chemokine CCL20 which can promote DC trafficking to the sites of tumor growth in a CCL20-CCR6 dependent manner. Recruitment of such DCs can effectively result in the priming and activation of CD8 T cells that result in enhanced CTL activity. In addition, IL-17 has been shown to promote maturation of DC progenitors (Antonysamy et al., [@B9]) and induce IL-12 production from macrophages (Jovanovic et al., [@B125]). Thus, these studies suggest that the combined cellular products from both Th17 and additional immune cells infiltrating the tumor, and the interaction between these cell types, may play a role in the balance between effective antitumor immunity and pro-tumor responses.

Investigations on the association between Th17 cells and promising clinical outcomes in cancer patients, have suggested a link and close interplay between the Th17 and Th1 cell lineages (Kryczek et al., [@B139]; Marshall et al., [@B171]). Within this positive association between intratumoral Th17 and IFN-γ-secreting Th1 cells, human Th17 cell populations producing both IL-17 and IFN-γ have been identified (Annunziato et al., [@B7]; Hamaï et al., [@B99]). It has been reported that these dual cytokine secreting cell populations are exclusively derived from Th17 cells and not initially differentiated Th1 cells (Hirota et al., [@B103]). These "converted" and/or "re-differentiated" Th17 cells express the Th1 related transcription factor T-bet in addition to the IL-17-related transcription factor ROR-γt (Annunziato et al., [@B7]). Stimulation by IL-12 rapidly down-regulated IL-17 production and induced expression of IFN-γ through enhanced T-bet expression and the subsequent down-regulation of ROR-γt expression (Annunziato et al., [@B7]; Annunziato and Romagnani, [@B8]; Lazarevic et al., [@B147]). Moreover, this shift in phenotype appeared to be facilitated by the low but constitutive expression of IL-12Rβ2 among Th17 cells (Annunziato et al., [@B7]; Lee et al., [@B152]). Thus these findings provided a molecular basis to explain Th17 cell plasticity and/or conversion to the Th1 cell lineage and further supports the concept that such events can occur within portions of the Th17 cell population under inflammatory conditions such as that of a hostile tumor environment *in vivo* (Muranski et al., [@B198]; Bending et al., [@B16]; Martin-Orozco et al., [@B156]; Annunziato and Romagnani, [@B8]; Murphy and Stockinger, [@B201]; Nistala et al., [@B208]; Hamaï et al., [@B99]; Marshall et al., [@B171]). This process of Th17 cellular plasticity appears highly context-dependent and can be influenced, in part, by the cytokine milieu produced by innate immune cells within the inflammatory environment. Consequently, such conversion of the Th17 cell population into the Th1 cell lineage, can have important biological implications in tumor immunity and disease progression. As mentioned earlier, both effector cell-derived IL-17 and IFN-γ can potentially promote or suppress the generation of effective immune responses through a myriad of different mechanisms (Xiao et al., [@B303]; Tosolini et al., [@B279]). Although the role of Th17 cells co-producing IL-17 and IFN-γ is not clear, it has been suggested that both cytokines can either synergistically or independently induce the production of functionally diverse chemokines within the tumor environment which in turn can recruit and promote distinct types of effector T cells and/or other immune cells that can influence antitumor immune responses and mediate tumor regression or progression (Kryczek et al., [@B140]; Martin-Orozco et al., [@B173]; Kesselring et al., [@B130]). Thus, it is conceivable that the relative quantity and/or duration of either IL-17 or IFN-γ produced by such double-positive cytokine secreting Th17 cell subpopulations may define the antitumor immune response. Moreover, the type of tumor, the cells within its microenvironment, and their responsiveness to the various tumor-associated cytokines may further promote and influence an imbalance between pro-tumor verses antitumor effects. For example, recent studies in the murine system by Huber et al., have shown that both IL-17- and IL-17/IFN-γ-producing Th17 cells express higher surface levels of the IL-10Rα when compared to that Th1 cells and that the potential antitumor or pro-tumor effects of the Th17-mediated inflammatory response can be more readily suppressed by endogenously produced IL-10 (Huber et al., [@B109]). Since many lineage-related tumor types can initially possess and generally favor similar microenvironments that can induce and selectively affect specific effector T cell-mediated responses, this may partially explain why Th17 cells have been observed and associated with protective tumor immunity in only some cancers but not all (Kryczek et al., [@B139]). The pro-tumor verses antitumor effects of such Th17 effector cell subpopulations may thus represent a "balance" between IL-17 and IFN-γ cytokine production that can facilitate either tumor promotion or regression. Further identification and characterization of the mechanisms involved in the induction of tumor-reactive Th17 effector cells and their activities in cancer patients may offer significant advantages for future treatment strategies of human malignancies.

CD4^+^ TReg cell subpopulations in immune regulation and the antitumor response
-------------------------------------------------------------------------------

The immunoregulatory roles of CD4^+^ TReg cell subsets have been associated with the prevention of immunopathology during excessive and/or unwanted inflammation and prevention of autoimmune disease. However, in the context of cancer, such cells have been associated with facilitating the suppression of the antitumor response through various tolerance induction and tissue homeostatic mechanisms. However, the role and prognostic value of TReg cells in cancer has recently been disputed (Wilke et al., [@B294]; Tosolini et al., [@B279]; deLeeuw et al., [@B60]). It has initially been reported that high TReg cell frequencies infiltrating the tumor environment correlate with more advanced disease and poor prognosis in patients. In ovarian, pancreatic, and breast cancer patients, either systemic or local FoxP3^+^ TReg cell expression has been associated with both a poor prognosis and diminished survival rates (Woo et al., [@B299]; Liyanage et al., [@B160]; Wolf et al., [@B297], [@B298]; Curiel et al., [@B56]; Li et al., [@B154]; Bates et al., [@B14]; Merlo et al., [@B180]). Curiel and colleagues reported that the presence of high numbers of CD4^+^FoxP3^+^ T cells in malignant ascites of patients with ovarian carcinomas correlated with advanced tumor staging and reduced survival. Alternatively, in colorectal cancer, several investigators did not find any differences between patients with high or low TReg cell infiltration (Loddenkemper et al., [@B161]) whereas others have found an improved survival associated with a high density of local and systemic FoxP3^+^ cells suggesting no major immunosuppressive role of TReg cells in colorectal cancer (Salama et al., [@B243]). Moreover, it has been suggested that the presence and levels of various TReg cell subsets in cancer patients may be beneficial to survival (Alvaro et al., [@B5]; Erdman et al., [@B76]; Grivennikov et al., [@B93]; Wilke et al., [@B294]; deLeeuw et al., [@B60]). None-the-less, in early clinical studies investigating adoptive T cell transfer therapies in patients with select cancer types, it was observed that TReg cell depletion prior to therapy can enhance clinically relevant immune responses to such treatments (Muranski et al., [@B199]; Wrzesinski et al., [@B300]; Dudley et al., [@B67]; Porter et al., [@B226]; Rosenberg et al., [@B236]; Le and Jaffee, [@B149]; Yao et al., [@B309]). These findings fit with the general notion that TReg cells suppress adaptive immune responses and led many groups to pursue various cytoablative strategies to deplete such cells from cancer patients receiving immunotherapy as a means to enhance clinical responses. In contrast, others have observed the induction of effective antitumor responses following administration of various immunotherapeutic strategies in the absence of cytoablative treatments, and have suggested that such responses are likely due to the balance between effector T cells (i.e., either CD4 or CD8) and TReg cells within treated cancer patients (Alvaro et al., [@B5]; Quezada et al., [@B229]; Hunder et al., [@B110]; Le and Jaffee, [@B149]; Liu et al., [@B157]). Along these lines, in our clinical study investigating adoptive T cell therapy using autologous Th1-like effector cells in the treatment of ovarian cancer patients, we observed enhanced T cell-mediated immune responses in long-term surviving patients that appeared to correlate with differences in their ratios of "inducible" verses "natural" TReg cell subpopulations when compared to that of short-term survivors receiving similar treatments (Dobrzanski et al., [@B62], [@B63]). We suggest that such patient responses did not appear to be dependent on TReg cell numbers but upon their subpopulation ratios within responding patients. Although the precise mechanisms by which these regulatory cells and their various subpopulations (and those that have yet to be defined) potentially function to establish or rebalance immune cell homeostasis and sustain the "balance" between tumor immunity, suppression, and tolerance remains poorly understood, it could be speculated that a collaboration and cross-talk among these various TReg subpopulations are required for the maintenance and control of effective immune responses. Thus, a conceivable role for co-therapeutic approaches targeting modulation, and not depletion, of the TReg cellular network in patients with select tumor types may be an alternative and potentially effective therapeutic approach to treating cancer patients.

Select chemokines and their corresponding receptors have been shown to play a role in the recruitment of specific T cell subsets into tumors and sites of inflammation (Sallusto et al., [@B246], [@B245]; Bonecchi et al., [@B24]; Loetscher et al., [@B163]; Hirai et al., [@B102]; Iellem et al., [@B113]; Muthuswamy et al., [@B203]). Among human TReg cells, the chemokine receptor CCR4, and its ligands CCL22 and CCL17, are believed to be the most predominant chemokine-related mechanism responsible for TReg cell trafficking to tumors (Iellem et al., [@B113]). It has been reported that production of the chemokine CCL22 is associated with human ovarian cancer (Iellem et al., [@B113]; Curiel et al., [@B56]) and has also been observed in other types of malignancies, such as gastric cancer (Haas et al., [@B97], [@B96]), Hodgkin's lymphoma (Ishida et al., [@B116]), and breast cancer (Menetrier-Caux et al., [@B178]). Blockade of CCL22 *in vivo* significantly reduced human TReg cell trafficking to ovarian carcinomas (Curiel et al., [@B56]). In a study on gastric cancer, CCL22 and CCL17 appeared to be both important in recruiting TReg cells to such tumors as demonstrated by *in vitro* migration assays (Mizukami et al., [@B189]). Additional observations in this same study further indicated that the levels of intratumoral CCL22 and CCL17 appeared to correlate with increased levels of TReg cell localization within these tumors at early stages of development. Besides the CCR4 chemokine receptor/ligand interaction, CCR5/CCL5 may also selectively recruit TReg cells to pancreatic tumors as shown in both human and murine systems (Tan et al., [@B273]). In addition, the chemokine CCL20 shows high affinity to TReg cells expressing CCR6 and has been shown to mediate selective CCR6^+^ TReg cell trafficking (Kleinewietfeld et al., [@B133]). In any instance, both naturally occurring (nTReg) or inducible (iTReg) CD4^+^ TReg cell subpopulations may become enriched within tumors, through a variety of different chemokine receptor/ligand interactions. Furthermore, cytokines and chemokines produced, in part, by either tumor cells, tumor infiltrating lymphocytes, and/or APCs within the tumor milieu may preferentially support such TReg cell expansion, retention, survival, and in some cases, their "further" differentiation and/or change in phenotype (Campbell and Koch, [@B29]). Following recruitment to sites of inflammation, one of the major functions of CD4^+^ TReg cell subsets is to maintain and/or restore local immune cell homeostasis during polarized Th1, Th2, and Th17 cell-mediated immune responses. This led to the identification and observation that human Th cell subsets and TReg cells appear to undergo functional specialization in parallel resulting in the development of functionally distinct TReg cell subsets capable of co-localizing with and effectively regulating different types of Th cell responses *in vivo* (Hall et al., [@B98]; Duhen et al., [@B68]). Although the precise mechanisms by which these various TReg cell subpopulations maintain or restore immune homeostasis at sites of inflammation and/or tumor growth is unknown, it is conceivable that such interactions that involve the local modulation of the naïve, effector, and memory Th cell pools can further influence antitumor responses that may favor either disease progression or regression. In addition, evidence is accumulating in several pre-clinical murine experimental models that a portion of CD4^+^ TReg cells can down-regulate FoxP3 expression and their associated regulatory properties and in some cases acquire an effector cell phenotype that expresses IFN-γ and/or IL-17 (Gavin et al., [@B89]; Strauss et al., [@B261]; Miyara et al., [@B188]; Oldenhove et al., [@B216]; Martin et al., [@B172]; Whiteside, [@B291]; Miyao et al., [@B186]). Although this concept and process of cellular conversion and/or plasticity among CD4^+^FoxP3^+^ TReg cells remains controversial (Rubtsov et al., [@B238]), it is clear that the biological properties of CD4 TReg cells and their subpopulations are heterogeneous and influenced by the tumor environment in which they infiltrate (Hamann, [@B100]; Sainz-Perez et al., [@B240]).

Alternatively, CD4^+^ TReg cells may possess other underappreciated anti-cancer functions. For example, such cells may have the ability to limit the extent and potential of inflammatory responses to induce tumor development and carcinogenesis. Using a murine herpes viral model, investigators observed that TReg cell-mediated down-modulation of inflammatory responses in secondary lymphoid tissues can actually optimize ensuing immune responses to local infection by more effectively redirecting it to sites of initial infection (Lund et al., [@B164]). These investigators further suggested that this down-modulation in inflammation within distal secondary lymphoid tissues following local viral infection can facilitate efficient effector T cell migration to sites of primary infection and more effectively promote disease eradication. Conceivably, this can be a concept that can also be applied to local sites of carcinogenesis and primary tumor growth. Moreover, others have suggested that, in colorectal and gastric cancers, CD4^+^ TReg cells may inhibit tumor-promoting inflammatory responses induced by local microbes, which may help explain their presence and favorable association with outcomes to these cancers (Haas et al., [@B96]; Zamarron and Chen, [@B313]). Thus the initial views on the role of TReg cells in carcinogenesis, tumor pathology, and tumor immunity appear oversimplified and in fact appear highly context-dependent with respect to their interactions with different components of a dynamic tumor environment.

Summary and Overall Thoughts
============================

The immune system has the capacity to either obstruct tumor development and deter established tumors, or to promote carcinogenesis and tumor progression. Here, we reviewed how CD4 T cells and their various functionally distinct subpopulations contribute to the antitumor immune response and potentially influence this process. Several key principles emerge. Distinct effector and memory CD4 T cell subsets have important roles in the antitumor response. Key among these roles is the provision of orchestrating and/or regulating other immune cells that result in promoting tumor eradication, long-term tumor immunity, and establishing or rebalancing immune cell homeostasis within the tumor environment. Such roles are mediated, in part, by the production of signature cytokines by specific CD4 T cell lineages and through direct cytotoxic effects on tumor cells. The efficacy of such CD4 effector T cell responses may not only depend on memory cell generation, phenotype, and their functional capacity to interact with other immune cell populations, but also in some cases, on their ability to evolve through "cellular plasticity" within the hostile tumor environment. Conceivably, this trait of "cellular Darwinism" by the various CD4 T cell lineages could endow them with considerable flexibility to procure effective tumor immunity. Alternatively, it appears that such CD4 T cell subsets and their signature cytokines can also contribute and facilitate tumor-promoting activities. This may be due, in part, on the abilities of select CD4 T cell lineages and their subpopulations to modulate effector cell population dynamics and thus affect the balance between effective and ineffective antitumor responses. Achieving an "appropriate cellular balance" appears highly context-dependent. Further studies on the biological activities and mechanisms of how the various polarized CD4 effector and/or memory T cell subsets influence and/or facilitate the immune response as a whole in patients with different types of cancers should further enhance the development of more effective cancer treatment strategies.
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